Cardiac fibrosis is a pathogenic factor of many cardiovascular diseases (CVD), which seriously affects people's life, and health and causes huge economic losses. Increasing evidence has shown that peroxisome proliferator-activated receptors (PPARs) can regulate the progression of cardiac fibrosis. For the first time, this review systematically summarizes the literature on cardiac fibrosis from the perspective of PPARs from 2010 to 2020. Moreover, the role of each PPARs in cardiac fibrosis was clarified in this scientific revision from the perspectives of pharmacologically active substances, known agonists, natural extract compounds, and nucleic-acid-based drugs in different CVD models. Furthermore, the combination of multiple PPARs on the treatment of cardiac fibrosis is discussed. This scientific review provides new ideas for targeting PPARs in the treatment of cardiac fibrosis and provides strategies for the development of new, safe, and effective pharmacological antagonists against cardiac fibrosis based on PPAR activity.

心脏纤维化是许多心血管疾病（CVD）的致病因素，严重影响人们的生活和健康，造成巨大的经济损失。越来越多的证据表明，过氧化物酶体增殖物激活受体 (PPAR) 可以调节心脏纤维化的进展。本综述首次从PPARs的角度对2010-2020年心脏纤维化相关文献进行系统总结，并从药理活性物质、已知激动剂的角度阐明了各PPARs在心脏纤维化中的作用。 、天然提取物化合物和不同 CVD 模型中的基于核酸的药物。此外，还讨论了多种 PPAR 的组合治疗心脏纤维化。